Document is current

Article History

Received: 10 September 2024

Accepted: 7 October 2024

First Online: 6 November 2024

Declarations

:

: The study received ethics approval in the United Kingdom from Yorkshire & The Humber- Leeds West Research Ethics Committee, Newcastle upon Tyne, UK on 2 April 2020 (REC ref: 20/YH/0133).In Australia, the approval was obtained from South Metropolitan Health Service Human Research Ethics Committee, MURDOCH, Western Australia on 3 September 2021 (ref: RGS0000004935) and 19 May 2022 (Ref: RGS0000005326), from St John of God Health Care Human Research Ethics Committee (ref: 1870) on 13 October 2021 and West Australian Aboriginal Health Ethics Committee (ref: HREC1146) on 29 April 2022.In New Zealand, the approval was obtained from Health and Disability Ethics Committees, Wellington, New Zealand, on 12 October 2021 (ref: 21/STH/213).Written informed consent will be obtained from all participants.

: Not applicable.

: A free of charge loan agreement between Royal Papworth Hospital NHS Foundation Trust and Fisher & Paykel for all AIRVO 2 HFNT devices and consumable needed for the completion of the study has been made. Fisher & Paykel however have not contributed to the study design or protocol and SAP development.AK or his institution has received unrestricted educational grant funding, honoraria or travel funding from Fisher and Paykel, Pharmacosmos, Masimo, Haemonetics and Nordic.